We are live on ! Find out more
EDIT icon

Editas Medicine

99 hedge funds and large institutions have $614M invested in Editas Medicine in 2017 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 32 increasing their positions, 17 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 15

88% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 17

61% more capital invested

Capital invested by funds: $381M → $614M (+$233M)

18% more funds holding

Funds holding: 8499 (+15)

3.54% more ownership

Funds ownership: 64.09%67.63% (+3.5%)

31% less call options, than puts

Call options by funds: $5.38M | Put options by funds: $7.75M

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

Holders
99
Holders Change
+15
Holders Change %
+17.86%
% of All Funds
2.46%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
35
Increased
32
Reduced
17
Closed
15
Calls
$5.38M
Puts
$7.75M
Net Calls
-$2.37M
Net Calls Change
-$2.61M
Name Holding Trade Value Shares
Change
Change in
Stake
CAG
26
Crestwood Advisors Group
Massachusetts
$2.37M +$2.4M +115,937 New
Hudson Bay Capital Management
27
Hudson Bay Capital Management
Connecticut
$2.23M +$2.07M +100,000 New
SM
28
Sabby Management
Florida
$2.02M -$512K -24,700 -21%
CGL
29
Clarius Group LLC
Washington
$1.95M
UBS Group
30
UBS Group
Switzerland
$1.75M +$1.43M +68,990 +748%
Wells Fargo
31
Wells Fargo
California
$1.45M +$318K +15,361 +31%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$1.42M +$457K +22,061 +53%
Thrivent Financial for Lutherans
33
Thrivent Financial for Lutherans
Minnesota
$1.14M +$1.06M +50,941 New
Group One Trading
34
Group One Trading
Illinois
$1.12M +$734K +35,404 +239%
GAMA
35
Graticule Asia Macro Advisors
New York
$1.12M +$1.04M +50,000 New
Janus Henderson Group
36
Janus Henderson Group
United Kingdom
$1.12M +$1.04M +50,000 New
OA
37
Omega Advisors
New York
$1.12M +$1.04M +50,000 New
PC
38
Paulson & Co
New York
$1.12M +$1.04M +50,000 New
Victory Capital Management
39
Victory Capital Management
Texas
$944K +$416K +20,092 +91%
Charles Schwab
40
Charles Schwab
California
$941K +$67.3K +3,249 +8%
WCM
41
Wildcat Capital Management
New York
$922K
Swiss National Bank
42
Swiss National Bank
Switzerland
$895K +$207K +10,000 +33%
TAM
43
Tocqueville Asset Management
New York
$781K +$725K +35,000 New
Goldman Sachs
44
Goldman Sachs
New York
$771K +$102K +4,945 +17%
TD Asset Management
45
TD Asset Management
Ontario, Canada
$754K +$58K +2,800 +9%
Tudor Investment Corp
46
Tudor Investment Corp
Connecticut
$584K +$543K +26,185 New
CIM
47
CIM Investment Management
Pennsylvania
$572K +$531K +25,616 New
TI
48
Trexquant Investment
Connecticut
$542K +$504K +24,303 New
AllianceBernstein
49
AllianceBernstein
Tennessee
$540K
ProShare Advisors
50
ProShare Advisors
Maryland
$454K -$103K -4,966 -20%

EDIT Hedge Fund Activity: Q1 2017 in Review

99 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2017, worth a combined $614M — up 61% from $381M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new EDIT positions and 15 closed out — a net gain of 20 holders — while 32 added to existing stakes and 17 trimmed.

The largest buyer was Capital World Investors, adding an estimated $30.6M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $10.2M sold.

  • 99 institutional investors held Editas Medicine (EDIT) as of Q1 2017, up from 84 in Q4 2016.
  • Funds reported $614M of Editas Medicine stock for Q1 2017, up 61% quarter-over-quarter.
  • 35 funds opened new Editas Medicine positions in Q1 2017 and 15 closed out, a net change of +20 holders.
  • The largest Editas Medicine buyer in Q1 2017 was Capital World Investors, an estimated $30.6M added.
  • The largest Editas Medicine seller in Q1 2017 was EcoR1 Capital, an estimated $10.2M sold.

Based on aggregated 13F filings for Q1 2017.